Medical Research and Biometrics Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 102300, China.
Coronary Heart Disease Center, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College, 167 Beilishi Rd, Beijing, 100037, China.
BMC Med. 2022 Jul 6;20(1):217. doi: 10.1186/s12916-022-02418-w.
Recent publications reported a paradoxical finding that there was an inverse association between the number of standard modifiable risk factors (SMuRFs; smoking, hypertension, diabetes, and hyperlipidemia) and mortality in patients with myocardial infarction. However, the current evidence is only limited to those highly developed countries with advanced medical management systems.
The China Acute Myocardial Infarction registry is a prospective observational study including patients with acute myocardial infarction from three-level hospitals across 31 administrative regions throughout mainland China. A total of 16,228 patients with first-presentation ST-elevation myocardial infarction (STEMI) admitted to hospitals from January 2013 to September 2014 were enrolled in the current analysis. Cox proportional hazard models adjusting for baseline characteristics, clinical profiles at presentation, and in-hospital treatments were used to assess the association of the number of SMuRFs with all-cause mortality at 30 days after STEMI presentation.
A total of 1918 (11.8%), 11,503 (70.9%), and 2807 (17.3%) patients had 0, 1-2, and 3-4 SMuRFs at presentation, respectively. Patients with fewer SMuRFs were older and more likely to be females, experienced longer pre-hospital delays, and were less likely to receive primary percutaneous coronary intervention and evidence-based medications. Compared with those without any SMuRF, patients with 1-2 SMuRFs and 3-4 SMuRFs were associated with an HR of 0.74 (95% CI, 0.63-0.87) and 0.63 (0.51-0.77) for all-cause mortality up to 30 days in the unadjusted model (P < 0.0001). However, after multivariate adjustment, the number of SMuRFs was positively associated with increased mortality risk (HR for 1-2 SMuRFs, 1.15 [0.95-1.39]; HR for 3-4 SMuRFs, 1.31 [1.02-1.68]; P = 0.03), and the association was only significant among patients admitted to hospitals beyond 12 h from onset (HR for 1-2 SMuRFs, 1.39 [1.03-1.87]; HR for 3-4 SMuRFs, 2.06 [1.41-3.01]) but not their counterparts (P = 0.01).
The increased crude mortality risk among patients without SMuRFs is explained by confounding factors related to their poor risk profiles (old age, longer pre-hospital delays, and poor clinical management). After multivariate adjustment, a higher risk-factor burden was associated with poor prognosis among patients with STEMI.
最近的研究报告显示了一个矛盾的发现,即心肌梗死患者的标准可修正危险因素(SMuRFs;吸烟、高血压、糖尿病和血脂异常)数量与死亡率之间呈负相关。然而,目前的证据仅局限于那些医疗管理系统先进的高度发达国家。
中国急性心肌梗死注册研究是一项前瞻性观察性研究,纳入了中国大陆 31 个行政区域三级医院的急性心肌梗死患者。共纳入了 2013 年 1 月至 2014 年 9 月期间首次就诊的 16228 例 ST 段抬高型心肌梗死(STEMI)患者。采用 Cox 比例风险模型,根据基线特征、就诊时的临床特征和院内治疗情况进行调整,评估就诊时 SMuRFs 数量与 STEMI 就诊后 30 天全因死亡率之间的关系。
就诊时,0、1-2、3-4 个 SMuRFs 的患者分别有 1918(11.8%)、11503(70.9%)和 2807(17.3%)例。SMuRFs 较少的患者年龄较大,更可能为女性,经历更长的院前延迟,更不可能接受直接经皮冠状动脉介入治疗和基于证据的药物治疗。与没有任何 SMuRFs 的患者相比,就诊时存在 1-2 个和 3-4 个 SMuRFs 的患者在未调整模型中 30 天全因死亡率的 HR 分别为 0.74(95%CI,0.63-0.87)和 0.63(0.51-0.77)(P<0.0001)。然而,在多变量调整后,SMuRFs 的数量与死亡率风险增加呈正相关(就诊时存在 1-2 个 SMuRFs 的 HR 为 1.15[0.95-1.39];就诊时存在 3-4 个 SMuRFs 的 HR 为 1.31[1.02-1.68];P=0.03),并且这种关联仅在发病后 12 小时以上入院的患者中具有显著性(就诊时存在 1-2 个 SMuRFs 的 HR 为 1.39[1.03-1.87];就诊时存在 3-4 个 SMuRFs 的 HR 为 2.06[1.41-3.01]),而在相应的对照组中则不具有显著性(P=0.01)。
无 SMuRFs 患者的粗死亡率增加是由与较差风险特征相关的混杂因素解释的(年龄较大、更长的院前延迟和较差的临床管理)。多变量调整后,STEMI 患者的危险因素负担越高,预后越差。